US 12,091,438 B2
Anti-mesothelin constructs and uses thereof
Ziyang Zhong, Belmont, CA (US); Fan Ye, Mountain View, CA (US); Matthew Siegel, Menlo Park, CA (US); and Jianing Huang, San Mateo, CA (US)
Assigned to Anwita Biosciences, Inc., San Carlos, CA (US)
Appl. No. 17/253,487
Filed by Anwita Biosciences, Inc., San Carlos, CA (US)
PCT Filed Jun. 17, 2019, PCT No. PCT/US2019/037557
§ 371(c)(1), (2) Date Dec. 17, 2020,
PCT Pub. No. WO2019/246003, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/809,496, filed on Feb. 22, 2019.
Claims priority of provisional application 62/686,481, filed on Jun. 18, 2018.
Prior Publication US 2021/0340272 A1, Nov. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/44 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C07K 14/765 (2006.01); C07K 16/30 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/54 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/765 (2013.01); C07K 16/30 (2013.01); C07K 16/44 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01)] 17 Claims
 
1. An isolated anti-mesothelin (anti-MSLN) construct comprising a single-domain antibody (sdAb) moiety that comprises an anti-MSLN heavy chain variable region (VH) comprising:
an HC-CDR1 comprising an amino acid sequence of SEQ ID NO: 27, an HC-CDR2 comprising an amino acid sequence of SEQ ID NO: 28, and an HC-CDR3 comprising an amino acid sequence of SEQ ID NO: 29.